Journal
MALARIA JOURNAL
Volume 21, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s12936-022-04173-y
Keywords
Malaria; Vectors; Transmission-blocking vaccines
Categories
Funding
- European & Developing Countries Clinical Trials Partnership (EDCTP) through the Multi-Stage Malaria Control Consortium [RIA2016V-1649]
- Wellcome Trust
- EDCTP grant
Ask authors/readers for more resources
This article discusses the immunological mechanisms underlying malaria transmission blocking, the status of Pfs25-based vaccines, and the approaches and capacity for first in-human evaluation in endemic settings. It is concluded that supporting low and middle income countries to conduct first-in human vaccine trials is crucial.
Malaria control relies heavily on the use of anti-malarial drugs and insecticides against malaria parasites and mosquito vectors. Drug and insecticide resistance threatens the effectiveness of conventional malarial interventions; alternative control approaches are, therefore, needed. The development of malaria transmission-blocking vaccines that target the sexual stages in humans or mosquito vectors is among new approaches being pursued. Here, the immunological mechanisms underlying malaria transmission blocking, status of Pfs25-based vaccines are viewed, as well as approaches and capacity for first in-human evaluation of a transmission-blocking candidate vaccine Pfs25-IMX313/Matrix-M administered to semi-immune healthy individuals in endemic settings. It is concluded that institutions in low and middle income settings should be supported to conduct first-in human vaccine trials in order to stimulate innovative research and reduce the overdependence on developed countries for research and local interventions against many diseases of public health importance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available